X4 Pharmaceuticals, INC Schedule 13G passive stakes

Deep Track Capital, along with affiliated entities, has reported beneficial ownership of 8.33% of X4 Pharmaceuticals' common stock as of June 30, 2026.

Perceptive Advisors LLC and Joseph Edelman have reported a 7.3% beneficial ownership stake in X4 Pharmaceuticals, Inc. via a Schedule 13G filing.

Morgan Stanley and its investment management arm, along with Inception Trust, have disclosed significant beneficial ownership in X4 Pharmaceuticals, Inc.

Saturn V Capital Management LP and Xiaoying Tian have reported a 7.36% beneficial ownership stake in X4 Pharmaceuticals, Inc. common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 2.80% beneficial ownership stake in X4 Pharmaceuticals, Inc. as of December 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a beneficial ownership of 9.4% in X4 Pharmaceuticals, Inc. common stock.

FMR LLC and Abigail P. Johnson have reported a 9.7% beneficial ownership stake in X4 Pharmaceuticals, Inc. common stock.

Empery Asset Management and Ryan M. Lane have reported a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., including shares from warrants, as of December 31, 2025.

Nantahala Capital Management and its principals reported a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc. as of September 30, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 14.8% beneficial ownership stake in X4 Pharmaceuticals Inc. common stock as of October 31, 2025.

Perceptive Advisors and its affiliates have reported a 7.6% beneficial ownership stake in X4 Pharmaceuticals, Inc., totaling 6,064,680 shares.

Empery Asset Management and its managing members have disclosed a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., including shares from warrants.

Coastlands Capital and its affiliates have reported a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., primarily through pre-funded warrants.

Bain Capital Life Sciences entities have disclosed a collective 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., signaling significant institutional interest.

Biotechnology Value Fund and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in X4 Pharmaceuticals, Inc., including shares from recently issued pre-funded warrants.

Deep Track Capital and affiliates have disclosed a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., holding 2,366,995 shares.

Trails Edge Capital Partners and affiliates have disclosed a 9.9% passive ownership stake in X4 Pharmaceuticals, Inc., holding 2,317,153 shares.

OrbiMed Advisors LLC has filed an Amendment No. 5 to its Schedule 13G, disclosing a 1.7% beneficial ownership in X4 Pharmaceuticals, Inc. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.0% beneficial ownership stake in X4 Pharmaceuticals, Inc. as of June 30, 2025.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.8% passive beneficial ownership stake in X4 Pharmaceuticals Inc. as of December 31, 2024.